Reversine Induces Apoptosis of FaDu Hypopharyngeal Carcinoma Cells
Background: Hypopharyngeal carcinoma is an aggressive subtype of head and neck squamous cell carcinoma, characterized by poor prognosis and resistance to conventional therapies. Reversine, a 2,6-disubstituted purine derivative, exhibits anticancer properties by inducing apoptosis and inhibiting ce...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Dental Hygiene Science
2024-12-01
|
| Series: | 치위생과학회지 |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Hypopharyngeal carcinoma is an aggressive subtype of head and neck squamous cell carcinoma, characterized by
poor prognosis and resistance to conventional therapies. Reversine, a 2,6-disubstituted purine derivative, exhibits anticancer
properties by inducing apoptosis and inhibiting cell proliferation in various cancers.
Methods: FaDu hypopharyngeal carcinoma cells were treated with reversine at concentrations of Control, 15 μM, and 30 μM. Cell
viability was assessed using MTT and live/dead assays. Apoptotic features were analyzed by hematoxylin & eosin and DAPI
staining, and DNA fragmentation assays. Immunoblotting was performed to evaluate caspase-3 and poly adenosine
diphosphate-ribose polymerase (PARP) activation.
Results: Reversine significantly reduced the viability of FaDu cells in a dose-dependent manner. Morphological changes, nuclear
fragmentation, and DNA laddering confirmed apoptosis. Immunoblotting revealed increased levels of cleaved caspase-3 and
PARP, indicating the activation of the intrinsic and extrinsic apoptotic pathways.
Conclusion: Reversine effectively inhibited FaDu cell viability and induced apoptosis through intrinsic and extrinsic pathways, and
represents a potential novel therapeutic agent for hypopharyngeal carcinoma. This study highlights a unique focus on
subpharyngeal cancer, overcoming therapeutic resistance, and suggests its potential as an anticancer agent by targeting dual
cell death pathways. |
|---|---|
| ISSN: | 2233-7679 |